COHANCE Cohance Lifesciences Q4 FY26 results (Jan–Mar 2026) and concall
Management summary
- Cohance Lifesciences reported a challenging FY26 with a 13% YoY revenue decline to INR 2,268 crores and an EBITDA margin of 21%, primarily due to destocking and customer inventory adjustments.
- Management expects Q1 FY27 to be weak, with recovery anticipated from H2 FY27.
- Execution on existing programs and new commercial launches..
- The company remains focused on strengthening its differentiated capabilities in ADCs and oligonucleotides and improving operational rigor.
Source: Inve concall analysis and management guidance record.
Highlights
-
Gross margin remained strong at 70.8% for FY26, supported by product mix, backward integration, and cost actions.
-
New business conversion with innovator pharma and biotech customers remains healthy.
-
The Phase 3 pipeline has expanded to 10 programs, with two molecules moving into commercialization.
-
API+ business saw sequential improvement in H2 FY26 with stabilized supply execution and strengthened customer engagement.
What they filed
Q4 FY26: revenue down 26.3%, net profit down 92.9% against the same quarter last year.
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 676 | 840 | 549 | 556 | 545 −19% | 619 −26% |
| EBITDA | 237 | 229 | 112 | 121 | 95 −60% | 99 −57% |
| Net profit | 153 | 117 | 46 | 66 | 29 −81% | 8 −93% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Guidance & targets
2Capex
Capex Spend Capex · FY27 · High confidence INR 3 billion
Revenue Growth
Overall Growth Revenue Growth · FY27 · Medium confidence return from second half
Source: Inve Guidance Tracker — management targets and direct quotes from the earnings call transcript.
Q&A highlights
2Contribution of large molecules and new commercial products to FY27 revenue Partial
Yes, so from a return, we are in active discussion with both the customers and we expect there would be a return in both these molecules. However, you will have to allow us to have meaningful conversations crystallize into orders before which we communicate to you on the actual a
Analysts sought specific quantification for revenue recovery from previously impacted products and new launches, but management provided only qualitative and directional timelines.
Asked by Karthi
Breakup of one-time expenses (INR109 crore) over last two years Direct
Yes. So I will tell you about this year. I think this year, on a one-time expenses, there are two large elements. One is that we have taken a one-off inventory provision, which is around 195 million. And we have also provided for certain customer adjustments, that is in the range
Management clarified the components of significant one-time expenses, providing transparency on non-recurring items impacting profitability.
Asked by Karthi
Unlock risks & concerns, Q1 FY27 watchlist, and full call analysis
You’re reading a preview. Opening the full call uses 1 concall credit and unlocks:
- 10 risks, concerns & management red flags
- 5 watchlist triggers for Q1 FY27
- +6 more guidance targets & verbatim management quotes
- +5 more analyst Q&A exchanges & evasion checks
- Capital allocation & full section-by-section narrative
Sign in to use your monthly call allowance.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared and our regulatory disclaimer. · Share on WhatsApp · Scorecard image





